kabutan

Chiome Bioscience Inc.(4583) Summary

4583
TSE Growth
Chiome Bioscience Inc.
112
JPY
-1
(-0.88%)
Jan 29, 3:30 pm JST
0.73
USD
Jan 29, 1:30 am EST
Result
PTS
outside of trading hours
111.1
Jan 29, 3:24 pm JST
Summary Chart Historical News Financial Result
PER
PBR
6.13
Yield
ー%
Margin Trading Ratio
946.00
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
112 JPY 0.73 USD
Previous Close Jan 28
113 JPY 0.74 USD
High Jan 29, 11:06 am
113 JPY 0.73 USD
Low Jan 29, 9:01 am
111 JPY 0.72 USD
Volume
287,800
Trading Value
0.03B JPY 0.21M USD
VWAP
111.62 JPY 0.73 USD
Minimum Trading Value
11,200 JPY 73 USD
Market Cap
7.67B JPY 0.05B USD
Number of Trades
136
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Slightly High
1-Year Average
457
1-Year High Feb 14, 2025
3,890
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 0 5,030,300
Jan 16, 2026 0 4,969,000
Jan 9, 2026 0 4,918,600
Dec 26, 2025 0 5,334,300
Dec 19, 2025 0 5,063,000
Company Profile
Chiome Bioscience Inc. is a drug discovery venture originating from RIKEN. The company specializes in proprietary antibody production technology and generates revenue through licensing.
Sector
Pharmaceuticals
Chiome Bioscience Inc. focuses on developing drug candidates for diseases with high unmet medical needs and supporting antibody drug discovery research, utilizing its core proprietary antibody production technology, the ADLib system. The company's main business area covers upstream processes from basic and exploratory research to preclinical development and early clinical development, with a basic strategy of early out-licensing of development candidate antibodies. In its drug discovery support business, Chiome Bioscience Inc. offers protein expression and purification services as well as antibody production services. The company integrates multiple antibody production technologies to maximize its antibody production capabilities. Chiome Bioscience Inc. has several in-house pipelines, including CBA-1205 and CBA-1535, and is actively promoting new drug discovery projects.